Related posts
Nervous markets await NvidiaThis summary was created by AI, based on 1 opinions in the last 12 months.
Solventum Corp (SOLV-N) has recently been the subject of mixed reviews from experts. One notable review indicates that a decision to sell the stock was not driven by a negative outlook, but rather due to a significant change in company dynamics, including a spin-off and the reduction of its dividend. This suggests that while some investors may be cautious, the underlying fundamentals of the company appear to be solid, characterized by decent earnings and an attractive valuation. The recent performance reports have been positive, which may indicate a potential turnaround for the stock. Overall, while there are concerns regarding dividend sustainability for certain investment strategies, the company's financial health seems to show promise, potentially making it a worthwhile consideration for growth-oriented investors.
3m completed spinning off healthcare company Solventum today. MMM shares have been challenged by many lawsuits, including over its hearing aids, and some of its businesses have slowed. An exception is Solventum, positing positive organic growth over the past decade. Revenues were $8.2 billion in 2023, but guidance said that 2024 will be a rebuilding year. That said, it's now selling at 11x this year's earnings, cheap. Keep in mind that most spun-offs start off shaky, with those getting initial shares not wanting them. So, buy Solventum gradually over the next 6 months. As for 3M, they paid dearly to settle their lawsuits, so the worst is behind them. Also, they're cutting costs like crazy. Also, Wall Street likes the change in CEOs.
Solventum Corp is a American stock, trading under the symbol SOLV-N on the New York Stock Exchange (SOLV). It is usually referred to as NYSE:SOLV or SOLV-N
In the last year, 1 stock analyst published opinions about SOLV-N. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Solventum Corp.
Solventum Corp was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Solventum Corp.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
In the last year, there was no coverage of Solventum Corp published on Stockchase.
On 2025-04-25, Solventum Corp (SOLV-N) stock closed at a price of $66.07.